Related Experiment Video
Updated: Jun 10, 2026
04:50
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Rheumatologists' recommended patient information when prescribing methotrexate for rheumatoid arthritis
1Department of Medicine, Division of Rheumatology, University of Western Ontario, London, Canada. andy.thompson@rogers.com
Clinical and Experimental Rheumatology
|July 29, 2010
Summary
Rheumatologists identified essential methotrexate information for patients, including dosing, risks like infection and lung toxicity, and when to contact a doctor. This ensures safer rheumatoid arthritis management.
Area of Science:
- Rheumatology
- Pharmacovigilance
- Patient Safety
Background:
- Effective communication of medication risks and benefits is crucial for patient adherence and safety.
- The complexity of information sources makes it challenging to convey essential details about methotrexate to rheumatoid arthritis patients.
Purpose of the Study:
- To determine the critical information rheumatoid arthritis patients need about methotrexate.
- To identify key reasons for patients to contact their physician while on methotrexate therapy.
Main Methods:
- A survey was distributed to 344 Canadian rheumatologists to gather their perspectives on essential patient knowledge and warning signs.
- Open-ended questions and emergent coding were employed to identify key themes and develop a comprehensive checklist.
- A second survey was used for validation of the established themes.
Main Results:
- A 49.5% response rate was achieved, with key information including regular blood testing, weekly dosing, infection risks, pregnancy/lactation precautions, alcohol limits, potential lung toxicity, and drug interactions highlighted.
- Patients were advised to contact their doctor if pregnant, experiencing symptoms of lung toxicity or infection, developing severe mouth sores, or concerned about side effects.
Conclusions:
- This study provides the first rheumatologist-driven overview of essential methotrexate information for patients.
- It clarifies critical knowledge points and specific circumstances under which patients should seek medical advice, enhancing methotrexate safety in rheumatoid arthritis care.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:20Rheumatic Heart Disease IV: Nursing Management
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...